The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), NVIDIA Corp.

Jedd Pagaduan is a certified Clippers and Gunners fan, which means he's a very sports-traumatized individual. He now writes about sports instead as a form of therapy.

With temps rising and school coming to a close, the age-old question on every local parent’s mind right now is: “What will my ...

It’s like watching America in miniature, all united by the universal language of “please pass the ketchup.” Morning at City ...

Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

BEAM-302 showed durable, dose-dependent correction of AATD mutation in 9 patients with effects seen as early as Day 7. Beam plans further dose escalation and will report new trial data in H2 2025 ...

has partnered with Belgium-based Ion Beam Applications (IBA), for its Proton Beam Therapy (PBT) based Proteus One system in India. Earlier in 2019, Apollo Hospitals had introduced proton therapy ...

Dr. Musunuru is a co-founder and equity holder of Verve Therapeutics, a gene therapy company, and receives funding from Beam Therapeutics for research, but not for this study. Dr. Richard P.

When proton therapy is first recommended for patients by their oncologist or primary care physician, or when a patient has learned about proton therapy as a treatment option another way, the first ...